Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

NCT02693171 · clinicaltrials.gov ↗

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Neuroblastoma

Interventions

DRUG: Dinutuximab

Sponsor

United Therapeutics